Arsanis is leading the development of targeted monoclonal antibodies (mAbs) for pre-emptive therapy and post-infection treatment of serious infectious diseases.
Arsanis appoints Rene Russo as President and CEO and also appoints David Mantus as Chief Development Officer and Ed Campanaro as SVP, Clinical Operations
Arsanis Appoints Michael P. Gray as Chief Financial Officer and Chief Business Officer